Meyka AI API is live for developers.Start building.
Advertisement
Rockwell Medical, Inc.

Rockwell Medical, Inc. Fundamental Analysis

RMTINASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.66
$0.03(4.72%)
U.S. Market opens in 52h 31m
Advertisement

Rockwell Medical, Inc. Fundamental Analysis

Rockwell Medical, Inc. (RMTI) shows weak financial fundamentals with a PE ratio of -4.88, profit margin of -7.98%, and ROE of -15.41%. The company generates $0.1B in annual revenue with weak year-over-year growth of -31.76%.

Key Strengths

Cash Position91.21%
PEG Ratio-0.01
Current Ratio3.74

Areas of Concern

ROE-15.41%
Operating Margin-7.11%
We analyze RMTI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -27.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-27.1/100

We analyze RMTI's fundamental strength across five key dimensions:

Efficiency Score

Weak

RMTI struggles to generate sufficient returns from assets.

ROA > 10%
-9.41%

Valuation Score

Excellent

RMTI trades at attractive valuation levels.

PE < 25
-4.88
PEG Ratio < 2
-0.01

Growth Score

Weak

RMTI faces weak or negative growth trends.

Revenue Growth > 5%
-31.76%
EPS Growth > 10%
-4.95%

Financial Health Score

Excellent

RMTI maintains a strong and stable balance sheet.

Debt/Equity < 1
0.40
Current Ratio > 1
3.74

Profitability Score

Weak

RMTI struggles to sustain strong margins.

ROE > 15%
-1541.06%
Net Margin ≥ 15%
-7.98%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is RMTI Expensive or Cheap?

P/E Ratio

RMTI trades at -4.88 times earnings. This suggests potential undervaluation.

-4.88

PEG Ratio

When adjusting for growth, RMTI's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Rockwell Medical, Inc. at 0.74 times its book value. This may indicate undervaluation.

0.74

EV/EBITDA

Enterprise value stands at -8.35 times EBITDA. This is generally considered low.

-8.35

How Well Does RMTI Make Money?

Net Profit Margin

For every $100 in sales, Rockwell Medical, Inc. keeps $-7.98 as profit after all expenses.

-7.98%

Operating Margin

Core operations generate -7.11 in profit for every $100 in revenue, before interest and taxes.

-7.11%

ROE

Management delivers $-15.41 in profit for every $100 of shareholder equity.

-15.41%

ROA

Rockwell Medical, Inc. generates $-9.41 in profit for every $100 in assets, demonstrating efficient asset deployment.

-9.41%

Following the Money - Real Cash Generation

Operating Cash Flow

Rockwell Medical, Inc. generates limited operating cash flow of $2.66M, signaling weaker underlying cash strength.

$2.66M

Free Cash Flow

Rockwell Medical, Inc. generates weak or negative free cash flow of $1.76M, restricting financial flexibility.

$1.76M

FCF Per Share

Each share generates $0.04 in free cash annually.

$0.04

FCF Yield

RMTI converts 6.72% of its market value into free cash.

6.72%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.74

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.39

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.40

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.74

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.15

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

-0.10

vs 25 benchmark

How RMTI Stacks Against Its Sector Peers

MetricRMTI ValueSector AveragePerformance
P/E Ratio-4.8829.20 Better (Cheaper)
ROE-15.41%729.00% Weak
Net Margin-7.98%-52856.00% (disorted) Weak
Debt/Equity0.400.49 Neutral
Current Ratio3.744.43 Strong Liquidity
ROA-9.41%-20711.00% (disorted) Weak

RMTI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Rockwell Medical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-78.72%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

96.71%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

99.58%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ